This announcement is a separate document:
诺诚健华医药有限公司自愿披露关于国家药品监督管理局受理tafasitamab联合来那度胺治疗复发或难治性弥漫性大B细胞淋巴瘤的生物制品许可的公告
Innocare Pharmaceuticals voluntarily disclosed an announcement regarding the acceptance by the National Medical Products Administration of the biological product license for tafasitamab and lenalidomide in the treatment of relapsed or refractory diffuse large B-cell lymphoma.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.